NCT06670456 Prospective Cohort of Patients With Intracerebral Hemorrhage
| NCT ID | NCT06670456 |
| Status | Recruiting |
| Phase | — |
| Sponsor | De-zhi Kang |
| Condition | Stroke, Acute |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2023-11-06 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2023-11-06 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators designed a multicentral, observational, prospective cohort study to provide cortical data for risk stratification and biomarkers on early outcomes, complications, long-term neurological function, and cognitive status of spontaneous intracerebral hemorrhage patients.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with spontaneous intracerebral hemorrhage (ICH) through skull radiologic scans (CT or MRI); * Underwent no surgical intervention; Exclusion Criteria: * Secondary intracerebral hemorrhage (with leading cause, e.g., Moyamoya disease, arteriovenous malformation, intracranial aneurysm, tumor, brain trauma) * Pre-stroke life expectancy \< 1 year for severe comorbidities (e.g., Progressive malignant tumor, severe chronic heart failure \[NYHA: III-IV\], severe chronic obstructive pulmonary disease \[III-IV\], chronic kidney disease requiring hemodialysis) * Severe dependency or incorporation to interview (e.g., pre-stroke mRS\>3, severe dementia, intractable mental disease) * Unsuitable for inclusion in the study in the opinion of the investigator
Contact & Investigator
De-zhi Kang, MD
PRINCIPAL INVESTIGATOR
First Affiliated Hospital of Fujian Medical University
Frequently Asked Questions
Who can join the NCT06670456 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06670456 currently recruiting?
Yes, NCT06670456 is actively recruiting participants. Contact the research team at kdz99988@vip.sina.com for enrollment information.
Where is the NCT06670456 trial being conducted?
This trial is being conducted at Fuzhou, China, Quanzhou, China, Quanzhou, China, Xiamen, China and 2 additional locations.
Who is sponsoring the NCT06670456 clinical trial?
NCT06670456 is sponsored by De-zhi Kang. The principal investigator is De-zhi Kang, MD at First Affiliated Hospital of Fujian Medical University. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.